Compare PSIX & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PSIX | MGTX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | 1000 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 960.7M | 909.1M |
| IPO Year | N/A | 2018 |
| Metric | PSIX | MGTX |
|---|---|---|
| Price | $41.60 | $10.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | ★ $99.95 | $24.57 |
| AVG Volume (30 Days) | ★ 1.1M | 617.7K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $81,391,000.00 |
| Revenue This Year | $24.73 | $141.38 |
| Revenue Next Year | $16.20 | N/A |
| P/E Ratio | $17.20 | ★ N/A |
| Revenue Growth | N/A | ★ 144.57 |
| 52 Week Low | $35.77 | $5.14 |
| 52 Week High | $121.47 | $11.85 |
| Indicator | PSIX | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.88 | 64.46 |
| Support Level | $35.77 | $7.11 |
| Resistance Level | $67.07 | $11.85 |
| Average True Range (ATR) | 4.69 | 0.43 |
| MACD | -0.02 | 0.05 |
| Stochastic Oscillator | 12.48 | 97.71 |
Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that run on nondiesel fuels, including natural gas, propane, and gasoline. The company's products are designed to meet emission standards imposed by environmental regulatory bodies like the Environmental Protection Agency. Its products are distributed to a wide range of industrial original equipment manufacturers that supply equipment to sectors including power generation, oil and gas, material handling, airport ground support, agricultural, turf, construction and irrigation. The company generates majority of its sales from United States, and also has its presence in North America (outside of United States), Pacific Rim, Europe and Others.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.